508 filings
Page 9 of 26
8-K
vrmel4jz
9 Aug 17
Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity
12:00am
S-8
n6irp5odzhd
9 Aug 17
Registration of securities for employees
12:00am
8-K
eta9mj7908oy
6 Jun 17
Regulation FD Disclosure
12:00am
424B5
jigmk7rt3qx4di
25 May 17
Prospectus supplement for primary offering
12:00am
8-K
g8zkd0
25 May 17
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
12:00am
424B5
14ck1ias8 lkb
23 May 17
Prospectus supplement for primary offering
12:00am
8-K
n9rbt7 1qlvjma1zp1
9 May 17
Departure of Directors or Certain Officers
12:00am
8-K
6nvgz3
5 May 17
Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity
12:00am
S-3ASR
ljv6l
5 May 17
Automatic shelf registration
12:00am
8-K
x9ocy1xln1vq
8 Feb 17
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity
12:00am
CT ORDER
l8qtb jo7997xaak48
7 Feb 17
Confidential treatment order
12:00am
8-K
lsko 3mox19meqas
3 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
d2fd wvgpkuv7xmciu
2 Nov 16
Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity
12:00am
8-K
jktali62gr3bem xh68
5 Oct 16
Alnylam Pharmaceuticals Discontinues Revusiran Development
12:00am
8-K
8zjta5o 4x6olm
19 Sep 16
Alnylam Expands and Strengthens Management Team as it Plans for Commercialization
12:00am